Eledon Q1 net loss $39M; cash $111.1M; 100% insulin independence in islet trial

Eledon Pharmaceuticals, Inc.

Cash, equivalents and short-term investments $111.1M as of March 31, 2026, down from $133.3M at Dec 31, 2025; funding expected into Q2 2027.
Net loss $39.0M ($0.33/share) vs $6.5M ($0.08/share) in Q1 2025; includes $19M non-cash loss from warrant liabilities.
R&D expense $17.2M (incl. $1.1M stock comp) vs $13.5M in prior year; G&A $4.0M vs $4.4M.
10/10 evaluable patients achieved 100% insulin independence with tegoprubart in islet transplantation; no rejection or tacrolimus-like toxicities.
FDA granted Orphan Drug designation for tegoprubart in liver transplantation; Phase 3 kidney trial design guidance expected from FDA.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Eledon Pharmaceuticals, Inc. reported first quarter 2026 results: net income Net loss for the first quarter of 2026 was $39.0 million, or $0.33 per basic common share, EPS $0.33 per basic common share.

Period: first quarter 2026
Net income: Net loss for the first quarter of 2026 was $39.0 million, or $0.33 per basic common share
EPS: $0.33 per basic common share
Result: reported results

Exact text from the filing

Net loss for the first quarter of 2026 was $39.0 million, or $0.33 per basic common share

View on SEC.gov

Browse all earnings releases →

Eledon Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-221658

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.